Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: Synergism with prostanoids and salbutamol

British Journal of Pharmacology

Volumn 123, Issue 6, 1998, Pages 1260-1266

  Au, B T ^a,b   Teixeira, M M ^a,c   Collins, P D ^a   Williams, T J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cyclic AMP PKA pathway; IL 8; Neutrophils; PDE4 inhibitors; Phagocytosis; Prostanoids; Zymosan

Indexed keywords

6 (5,6 DIMETHOXYBENZO[B]THIEN 2 YL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; CILOMILAST; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; INTERLEUKIN 8; KT 5720; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTANOID; ROLIPRAM; SALBUTAMOL; UNCLASSIFIED DRUG; ZAPRINAST; ZYMOSAN;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; ALBUTEROL; BENZAMIDES; CYCLOHEXANECARBOXYLIC ACIDS; DRUG SYNERGISM; HUMANS; INTERLEUKIN-8; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; PYRIDINES; PYRROLIDINONES; ROLIPRAM; ZYMOSAN;

EID: 0031935312     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701723     Document Type: Article

References (41)

1. AU, B-T., WILLIAMS, T.J. & COLLINS, P.D. (1994). Zymosan-induced interleukin-8 release from human neutrophils involves activation via the CD11b/CD18 receptor and endogenous platelet activating factor as an autocrine modulator. J. Immunol., 152, 5411 5419.
2. BAGGIOLINI, M. & CLARK-LEWIS, I. (1992). Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Letts. 307, 97 101.
3. BARNETTE, M.S., CHRISTENSEN, S. B., ESSAYAN, D.M., ESSER, K.M., GROUS, M., HUANG, S., MANNING, C.D., PRABHAKAR, U., RUSH J. & TORPHY, T.J. (1994). SB 207499, a potent and selective phosphodiesterase (PDE) IV inhibitor, suppresses activates of several immune and inflammatory cells. Am. J. Resp. Crit. Care. Med., 149, A209(Abstract).
4. BAZZONI, F., CASSATELLA, M.A., ROSSI, F., CESKA, M., DEWALD, B. & BAGGIOLINI, M. (1991). Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J. Exp. Med., 173, 771-774.
5. BEAVO, J.A. (1988). Multiple isozymes of cyclic nucleotide phosphodiesterase. In Advances in Second Messenger and Phosphoprotein Research. Vol 22. ed. Greengard, P. & Robison, G.A. pp. 1-38. New York: Raven Press.
6. BEAVO, J.A., CONTI, M. & HEASLIP, R.J. (1994). Multiple cyclic nucleotyde phosphodiesterases. Mol. Pharmacol., 46, 399-405.
7. BRANDT, E., PETERSEN, F. & FLAD, H.D. (1992). Recombinant tumor necrosis factor-alpha potentiates neutrophil degranulation in response to host defence cytokines neutrophil-activating peptide 2 and IL-8 by modulating intracellular cyclic AMP levels. J. Immunol., 149, 1356-1364.
8. BRENNAN, F.M., ZACHARIAE, C.O.C., CHANTRY, D., LARSEN, C.G., TURNER, M., MAINI, R.N., MATSUSHIMA, K. & FELDMANN, M. (1990). Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur. J. Immunol., 20, 2141-2144.
9. CHOLLET-MARTIN, S., JOURDAIN, B., GIBERT, C., ELBIM, C., CHASTRE, J. & GOUHEROT-POCIDALO, M.A. (1996). Interactions between neutrophils and cytokines in blood and alveolar spaces during ADRS. Am. J. Respir. Crit. Care. Med., 154, 594-601.
10. COHAN, V.L., SHOWELL, H.J., FISHER, D.A., PAZOLES, C.J., WATSON, J.W., TURNER, C.R. & CHENG, J.B. (1996). In vitro pharmacology of the novel phosphodiesterase Type 4 inhibitor, CP-80633. J. Pharmacol. Exp. Ther., 278, 1356-1361.
11. CROMWELL, O., HAMID, Q., CORRIGAN, C.J., BARKANS, J., MENG, Q., COLLINS, P.D. & KAY, A.B. (1992). Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor bronchial epithelial cells and enhancement by IL-1β and tumour necrosis factor-α. Immunology, 77, 330-337.
12. DARIUS, H., MICHAEL-HEPP, J., THIERAUCH, K.H. & FISCH, A. (1994). Inhibition of human platelets and polymorphonuclear neutrophils by the potent and metabolically stable prostaglandin D2 analogue ZK 118.182. Eur. J. Pharmacol., 258, 207-213.
13. DRAKE, W.T. & ISSEKUTZ, A.C. (1993). Transforming growth factor-β1 enhances polymorphonuclear leukocyte accumulation in dermal inflammation and transendothelial migration by a priming action. Immunology 78, 197-204.
14. GRIFFITHS, M.J.D. & EVANS, T.W. (1996). ARDS. Acute Respiratory Distress in Adults. In Prospects for Pharmacotherapy. ed. Evans, T.W. & Haslett, C. pp. 507-524. London: Chapman & Hall.
15. HENSON, P.M. (1971). The immunologic release of constituents from neutrophil leukocytes. II. Mechanisms of release during phagocytosis, and adherence to nonphagocytosable surfaces. J. Immunol., 107, 1547-1557.
16. IRIE, K., TOKUDA, H., HAGIWARA, N., KOSHIMIZU, K., HAYASHI, H., MURAO, S. & ITO, Y. (1985). Structure-activity relationship in the induction of Epstein-Barr virus teleocidin derivatives. Int. J. Cancer 36, 485-488.
17. KAMMER, G.M. (1988). The adenylate cyclase - cAMP - protein kinase A pathway and regulation of the immune response. Immunol. Today, 9, 222-229.
18. KUEHL, F.A., ZANETTI, M.E., SODERMAN, D.D., MILLER, D.K. & HAM, E.A. (1987). Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma. Am. Rev. Respir. Dis., 136, 210-213.
19. KUNKEL, S.L., STANDIFORD, T., KASAHARA, K. & STRIETER, R.M. (1991). Interleukin-8 (IL-8): The major neutrophil chemotactic factor in the lung. Exp. Lung Res., 17, 17-23.
20. MILLER, E.J., COHEN, A.B., NAGAO, S., GRIFFITH, D., MAUNDER, R.J., MARTIN, T.R., WEINER-KRONISH, J.P., STICHERLING, M., CHRISTOPHERS, E. & MATTHAY, M.A. (1992). Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. Am. Rev. Respir. Dis., 146, 427-432.
21. MIOTLA, J.M., TEIXEIRA, M.M. & HELLEWELL, P.G. (1998). Suppression of acute lung injury by an inhibitor of phosphodiesterase type 4. Am. J. Respir. Cell Mol. Biol., (in press).
22. MUKAIDA, N., SHIROO, M. & MATSUSHIMA, K. (1989). Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J. Immunol., 143, 1366-1371.
23. MULLER, T., ENGELS, P. & FOZARD, J.R. (1996). Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. Sci., 17, 294-298.
24. NELSON, S., SUMMER, W.R. & JAKAB, G.J. (1985). Aminophylline-induced suppression of pulmonary antibacterial defenses. Am. Rev. Respir. Dis., 131, 923-927.
25. NICHOLSON, C.D. & SHAHID, M. (1994). Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes -their potential utility in the therapy of asthma. Pulm. Pharmacol., 7, 1-17.
26. NICKOLOFF, B.J., KARABIN, G.D., BARKER, J.N.W., GRIFFITHS, C.E.M., SARMA, V., MITRA, R.S., ELDER, J.T., KUNKEL, S.L. & DIXIT, V.M. (1991). Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am. J. Pathol., 138, 129-140.
27. NIELSON, C.P., VESTAL, R.E., STURM, R.J. & HEASLIP, R. (1990). Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol., 86, 801-808.
28. NOURSHARGH, S., PERKINS, J.A., SHOWELL, H.J., MATSUSHIMA, K., WILLIAMS, T.J. & COLLINS, P.D. (1992). A comparative study of the neutrophil stimulatory activity in vitro and proinflammatory properties in vivo of 72 amino acid and 77 amino acid IL-8. J. Immunol., 148, 106-111.
29. RAMPART, M., HERMAN, A.G., GRILLET, B., OPDENAKKER, G. & VAN DAMME, J. (1992). Development and application of a radioimmunoassay for interleukin-8: detection of interleukin-8 in synovial fluids from patients with inflammatory joint disease. Lab. Invest., 66, 512-518.
30. RIVKIN, I., ROSENBLATT, J. & BECKER, E.L. (1975). The role of cyclic AMP in the chemotactic responsiveness and spontaneous motility of rabbit peritoneal neutrophils. The inhibition of neutrophil movement and the elevation of cyclic AMP levels by catecholamines, prostaglandins, theophylline and cholera toxin. J. Immunol., 115, 1126-1134.
31. i. Naunyn-Schmiedeberg's Arch. Pharmacol., 344, 682-690.
32. STRIETER, R.M., KASAHARA, K., ALLEN, R.M., STANDIFORD, T.J., ROLFE, M.W., BECKER, F.S., CHENSUE, S.W. & KUNKEL, S.L. (1992). Cytokine-induced neutrophil-derived interleukin-8. Am. J. Pathol., 141, 397-407.
33. STRIETER, R.M. & KUNKEL, S.L. (1994). Acute lung injury: the role of cytokines in the elicitation of neutrophils. J. Invest. Med., 42, 640-651.
34. 2, forskolin, and dibutyryl cAMP on arachidonic acid release and inositol phospholipid metabolism in guinea pig neutrophils. J. Biol. Chem., 261, 1092-1098.
35. TEIXEIRA, M.M., GRISTWOOD, R.W., COOPER, N. & HELLEWELL, P.G. (1997). Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol. Sci., 18, 164-170.
36. TORRE, D., ZEROLI, C., GIOLA, M., FIORI, G.P., MINOJA, G., MARAGGIA, D. & CHIARANDA, M. (1993). Levels of interleukin-8 in patients with adult respiratory distress syndrome. J. Infect. Dis., 167, 505-506.
37. TURNER, C.R., ESSER, K.M. & WHEELDON, E.R. (1993). Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circ. Shock, 39, 237-245.
38. WEISSMANN, G., ZURIER, R.B., SPIELER, P.J. & GOLDSTEIN, I.M. (1971). Mechanisms of lysosomal enzyme release from leukocytes exposed to immune complexes and other particles. J. Exp. Med., 134, 149.
39. 2, dexamethasone, and IL-4. J Immunol., 151, 2166-2175.
40. WORTHEN, G.S. & DOWNEY, G.P. (1996). ARDS. Acute Respiratory Distress in Adults. In Mechanisms of Neutrophil Mediated Injury. ed. Evans, T.W. & Haslett, C. pp. 99-114. London: Chapman & Hall.
41. ZURBONSEN, K., MICHEL, A., VITTET, D., BONNET, P. & CHEVILLARD, C. (1997). Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line. Biochem. Pharm., 53, 1141-1147.